Novo Nordisk Surges to Top 50 Most Traded Stocks with 12.08 Billion Turnover Amid Weight Loss Market Competition

On June 2, 2025, Novo Nordisk (NVO) saw a significant increase in trading volume, with a turnover of 12.08 billion, marking a 52.5% rise from the previous day. This surge placed NVO among the top 50 most traded stocks for the day. The stock price of NVO rose by 1.86%, marking the third consecutive day of gains, with a total increase of 6.17% over the past three days.

Novo Nordisk's early dominance in the weight loss industry was largely attributed to its drug Ozempic. However, the company is now facing intensified competition, which has led to a 52% drop in its stock value. This decline raises questions about whether Novo Nordisk is losing its leadership position in the $150 billion weight loss market.

Despite the challenges, Novo Nordisk remains a key player in the global healthcare sector, particularly in diabetes care, hemophilia treatment, growth hormone therapy, and obesity management. The company operates through two main segments: Diabetes and Obesity Care, and Other.